Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Clinical Applications of Pharmacogenomics in Cancer Therapy
175
Answer Key
1. d
2.
Chemotherapy
Biomarkers
H Oxaliplatin a. MTHFR
E Cyclophosphamide b. G6PD
B Dabrafenib c. UGT1A1
C Irinotecan d. DPD
F Tamoxifen e. CYP2B6
G 6-MP f. CYP2D6
A Methotrexate g. TPMT
D Capecitabine h. ERCC1
3. A reduction in the starting dose of irinotecan for any patient homozygous
for the UGT1A1*28 allele
4. d
5. b
REFERENCES
1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and
mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.
2. Albertini L, Siest G, Jeannesson E, Visvikis-Siest S. Availability of pharmacogenetic
and pharmacogenomic information in anticancer drug monographs in France:
Personalized cancer therapy. Pharmacogenomics. 2011;12:681–91.
3. McLeord HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurinemethyltransferase
and its clinical relevance for childhood acute lymphoblastic
leukemia. Leukemia. 2000;14:567–72.
4. Feng X, Pearson D, Listiawan M, Cheung C. Pharmacogenomic biomarkers for toxicities
associated with cancer therapy. US Pharmacist. 2012;37(1):2–7.
5. Feng X, Vyas D, Guan B. Novel immune and target therapy for skin cancer. US
Pharmacist. 2012;37(11):7–11.
6. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized
patients: A meta-analysis of prospective studies. JAMA. 1998;279:1200– 205.
7. Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics:
A bridge to individualized cancer therapy. Pharmacogenomics. 2013;14(3):15–24.
8. Feng X, Brazill B, Pearson D. Therapeutic application of pharmacogenomics in oncology:
Selective biomarkers for cancer treatment. US Pharmacist. 2011;36(11):5–12.
9. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype
and irinotecan-induced neutropenia: Dose matters. J. Natl Cancer Inst. 2007;99:1290–95.
10. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on
pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter
randomized trial of patients with metastatic colorectal cancer. J Clin Oncol.
2008;26:2099–105.
11. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for
fluorouracil treatment-related severe toxicity: A prospective clinical trial by the
German 5-FU toxicity study group. J Clin Oncol. 2008;26:2131–38.
12. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase
deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
J Clin Oncol. 2001;19:2293–301.